Skip to main content
Top

17-02-2017 | Bladder cancer | Article

The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence

Journal: Journal of Cancer Survivorship

Authors: Amanda J. Edmondson, Jacqueline C. Birtwistle, James W.F. Catto, Maureen Twiddy

Publisher: Springer US

Abstract

Purpose

Bladder cancer (BC) is a common disease with disparate treatment options and variable outcomes. Despite the disease’s high prevalence, little is known of the lived experience of affected patients. National patient experience surveys suggest that those with BC have poorer experiences than those with other common cancers. The aim of this review is to identify first-hand accounts of the lived experiences of diagnosis through to survivorship.

Method

This is a systematic review of the qualitative evidence reporting first-hand accounts of the experiences of being diagnosed with, treated for and surviving bladder cancer. A thematic analysis and ‘best-fit’ framework synthesis was undertaken to classify these experiences.

Results

The inconsistent nature of symptoms contributes to delays in diagnosis. Post-diagnosis, many patients are not actively engaged in the treatment decision-making process and rely on their doctor’s expertise. This can result in patients not adequately exploring the consequences of these decisions. Learning how to cope with a ‘post-surgery body’, changing sexuality and incontinence are distressing. Much less is known about the quality of life of patients receiving conservative treatments such as Bacillus Calmette-Guerin (BCG).

Conclusions

The review contributes to a greater understanding of the lived experience of bladder cancer. Findings reflect a paucity of relevant literature and a need to develop more sensitive patient-reported outcome measures (PROMs) and incorporate patient-reported outcomes in BC care pathways.

Implications for cancer survivors

Collective knowledge of the patients’ self-reported experience of the cancer care pathway will facilitate understanding of the outcomes following treatment.
Literature
1.
Chavan S, Bray F, Lortet-Teulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol. 2014;66:59–73.CrossRefPubMed
2.
Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253–62. doi:10.​1016/​j.​eururo.​2014.​01.​006.CrossRefPubMed
3.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41. doi:10.​1016/​j.​eururo.​2012.​07.​033.CrossRefPubMed
4.
Ali AS, Hayes MC, Birch B, Dudderidge T, Somani BK. Health related quality of life (HRQoL) after cystectomy: comparison between orthotopic neobladder and ileal conduit diversion. European journal of surgical oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015;41(3):295–9. doi:10.​1016/​j.​ejso.​2014.​05.​006.CrossRef
5.
National Cancer Survivorship Initiative. Vision document. 2010. http://​www.​ncsi.​org.​uk/​
6.
Department of Health. National Cancer Patient Experience Survey 2011/12—national report 2012.
7.
Dale HL, Adair PM, Humphris GM. Systematic review of post-treatment psychosocial and behaviour change interventions for men with cancer. Psychooncology. 2010;19(3):227–37. doi:10.​1002/​pon.​1598.CrossRefPubMed
8.
Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD, et al. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol. 2014;66(6):1148–56. doi:10.​1016/​j.​eururo.​2014.​02.​034.CrossRefPubMedPubMedCentral
9.
Nikapota AD, Cresswell J, Appleyard S, Catt SL. Quality of life after bladder cancer: a prospective study comparing patient-related outcomes after radical surgery or radical radiotherapy for bladder cancer. Clin Oncol. 28(6):373–5. doi:10.​1016/​j.​clon.​2015.​12.​002.
10.
Sanchez A, Wszolek MF. Bladder cancer: quality of life in patients with non-muscle-invasive bladder cancer. Nat Rev Urol. 2015;12(4):186–8. doi:10.​1038/​nrurol.​2015.​12.CrossRefPubMed
11.
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.CrossRefPubMed
12.
Wright JL, Porter MP. Quality-of-life assessment in patients with bladder cancer. Nat Clin Pract Urol. 2007;4(3):147–54.CrossRefPubMed
13.
Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005;173(4):1318–22. doi:10.​1097/​01.​ju.​0000149080.​82697.​65.CrossRefPubMed
14.
Allareddy V, Kennedy J, West MM, Konety BR. Quality of life in long-term survivors of bladder cancer. Cancer. 2006;106(11):2355–62. doi:10.​1002/​cncr.​21896.CrossRefPubMed
15.
Cerruto MA, D’Elia C, Cacciamani G, De Marchi D, Siracusano S, Iafrate M et al. Behavioural profile and human adaptation of survivors after radical cystectomy and ileal conduit. Health and Quality of Life Outcomes. 2014;12(1).
16.
Lasch KE, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, et al. PRO development: rigorous qualitative research as the crucial foundation. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 2010;19(8):1087–96. doi:10.​1007/​s11136-010-9677-6.CrossRef
17.
Duncan R, Essat M, Jones G, Booth A, Buckley Wood H, Poku E et al. Patient-reported outcome measures for abdominal aortic aneurysm: a systematic review and qualitative evidence synthesis. British Journal of Surgery. 2016 (in press). doi:DOI: 10.​1002/​bjs.​10407
18.
Carroll C, Booth A, Cooper K. A worked example of “best fit” framework synthesis: a systematic review of views concerning the taking of some preventive chemopreventive agents BMC Medical Research Methodology. 2011;11(29).
19.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.​1371/​journal.​pmed.​1000097.CrossRefPubMedPubMedCentral
20.
Critical Appraisal Skills Programme. CASP Qualitative Checklist. 2013. http://​www.​casp-uk.​net/​#!casp-tools-checklists/​c18f8.
21.
Beitz JM, Zuzelo PR. The lived experience of having a neobladder...including commentary Artinian BM and Watson LA with author response. West J Nurs Res. 2003;25(3):294–321. 28pCrossRefPubMed
22.
Clark M, Harris N, Martin S, Bartley K, DeBusk K, Abidoye O et al. The impact of non muscle invasive bladder cancer: qualitative research with patients. ISPOR 18th Annual European Congress; Milan, Italy. INCLUDED2015
23.
Fitch MI, Miller D, Sharir S, McAndrew A. Radical cystectomy for bladder cancer: a qualitative study of patient experiences and implications for practice. Canadian oncology nursing journal =. Revue canadienne de nursing oncologique. 2010;20(4):177–87.CrossRefPubMed
24.
Hilton E, Henderson L. Lived female experience of chronic bladder cancer: a phenomenologic case study. Urologic Nursing. 2003.
25.
Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey. BMJ Open. 2013;3(6) doi:10.​1136/​bmjopen-2013-002861.
26.
Williams-Cox D. A mixed-method study into quality of life for bladder cancer patients. Professional Nurse. 2004;19(6):343–7.
27.
Mohamed NE, Chaoprang HP, Hudson S, Revenson TA, Lee CT, Quale DZ, et al. Muscle invasive bladder cancer: examining survivors’ burden and unmet needs. J Urol. 2014;191(1):48–53. doi:10.​1016/​j.​juro.​2013.​07.​062.CrossRefPubMed
28.
Berry DL, Nayak M, Halpenny B, Harrington S, Loughlin KR, Chang P, et al. Treatment decision making in patients with bladder cancer. Bladder Cancer. 2015;1(2):151–8.CrossRefPubMedPubMedCentral
29.
Perlis N. Developing the bladder utility symptom scale: a multiattribute health state classification system for bladder cancer: University of Toronto; 2013.
30.
Skea Z, MacLennan S, Entwistle V, N’Dow J. Communicating good care: a qualitative study of what people with urological cancer value in interactions with health care providers. Eur J Oncol Nurs. 2014;18(1):35–40.CrossRefPubMed
31.
Patel HR, Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, et al. Enhanced recovery after surgery: are we ready, and can we afford not to implement these pathways for patients undergoing radical cystectomy? Eur Urol. 2014;65(2):263–6. doi:10.​1016/​j.​eururo.​2013.​10.​011.CrossRefPubMed
32.
Persson E, Hellstrom AL. Experiences of Swedish men and women 6 to 12 weeks after ostomy surgery. J Wound Ostomy Continence Nurs. 2002;29(2):103–8.PubMed
33.
Foley KL, Farmer DF, Petronis VM, Smith RG, McGraw S, Smith K, et al. A qualitative exploration of the cancer experience among long-term survivors: comparisons by cancer type, ethnicity, gender, and age. Psycho Oncology. 2006;15(3):248–58.CrossRefPubMed
34.
Treanor C, Donnelly M. Late effects of cancer and cancer treatment—the perspective of the patient. Support Care Cancer. 2016;24(1):337–46. doi:10.​1007/​s00520-015-2796-4.CrossRefPubMed
35.
Kowalkowski MA, Chandrashekar A, Amiel GE, Lerner SP, Wittmann D, Latini DM, et al. Examining sexual dysfunction in non-muscle-invasive bladder cancer: results of cross-sectional mixed-methods research. Sexual Medicine. 2014;2:141–51.CrossRefPubMedPubMedCentral
36.
Public Health England. Living with and beyond bladder cancer: a descriptive summary of responses to a pilot of Patient Reported Outcomes Measures for Bladder Cancer 2015.
37.
Somani BK, Gimlin D, Fayers P, N’Dow J. Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion—a prospective cohort study with a systematic review of literature. Urology. 2009;74(5):1138–43. doi:10.​1016/​j.​urology.​2009.​05.​087.CrossRefPubMed
38.
Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007;109(9):1756–62. doi:10.​1002/​cncr.​22556.CrossRefPubMed
39.
Administration USDoHaHSFaD. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. . 2009. http://​www.​fda.​gov/​downloads/​Drugs/​Guidances/​UCM193282.​pdf.
40.
Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B. Patient-reported outcomes: conceptual issues. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2007;10(Suppl 2):S66–75. doi:10.​1111/​j.​1524-4733.​2007.​00269.​x.CrossRef
41.
Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS. Patient-reported outcomes: instrument development and selection issues. Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2007;10(Suppl 2):S86–93. doi:10.​1111/​j.​1524-4733.​2007.​00271.​x.CrossRef